| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Galectin Therapeutics Inc.
13D/A
GALT · 363225202
|
49.3% |
8/4/2026
Event 7/31/2026
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.